MA44922A1 - Anticorps - Google Patents

Anticorps

Info

Publication number
MA44922A1
MA44922A1 MA44922A MA44922A MA44922A1 MA 44922 A1 MA44922 A1 MA 44922A1 MA 44922 A MA44922 A MA 44922A MA 44922 A MA44922 A MA 44922A MA 44922 A1 MA44922 A1 MA 44922A1
Authority
MA
Morocco
Prior art keywords
antibody
binding
fragment
present
dna
Prior art date
Application number
MA44922A
Other languages
English (en)
Other versions
MA44922B1 (fr
Inventor
Graham Craggs
Karine Jeannine Madeleine Herve
Diane Marshall
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49397073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA44922(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of MA44922A1 publication Critical patent/MA44922A1/fr
Publication of MA44922B1 publication Critical patent/MA44922B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)

Abstract

La présente invention concerne un anticorps anti-csf-1r et des fragments de liaison associés, de l'adn codant pour celui-ci, des cellules hôtes comportant ledit adn et des méthodes d'expression de l'anticorps ou d'un fragment de liaison dans une cellule hôte. La présente invention s'étend également à des compositions pharmaceutiques comprenant l'anticorps ou un fragment de liaison associé, et l'utilisation de l'anticorps, du fragment de liaison et des compositions les comprenant dans un traitement.
MA44922A 2013-08-30 2014-08-26 Anticorps MA44922B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1315487.7A GB201315487D0 (en) 2013-08-30 2013-08-30 Antibodies
PCT/EP2014/068050 WO2015028455A1 (fr) 2013-08-30 2014-08-26 Anticorps

Publications (2)

Publication Number Publication Date
MA44922A1 true MA44922A1 (fr) 2019-08-30
MA44922B1 MA44922B1 (fr) 2020-06-30

Family

ID=49397073

Family Applications (2)

Application Number Title Priority Date Filing Date
MA38930A MA38930A1 (fr) 2013-08-30 2014-08-26 Anticorps, anti-récépteur du facteur de stimulation des colonies (csf1r)
MA44922A MA44922B1 (fr) 2013-08-30 2014-08-26 Anticorps

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA38930A MA38930A1 (fr) 2013-08-30 2014-08-26 Anticorps, anti-récépteur du facteur de stimulation des colonies (csf1r)

Country Status (39)

Country Link
US (2) US9908939B2 (fr)
EP (3) EP3549599B1 (fr)
JP (3) JP6632075B2 (fr)
KR (1) KR102303130B1 (fr)
CN (2) CN105658236B (fr)
AR (2) AR097464A1 (fr)
AU (1) AU2014314304B2 (fr)
BR (1) BR112016004324B1 (fr)
CA (1) CA2922240C (fr)
CL (1) CL2016000438A1 (fr)
CY (1) CY1121964T1 (fr)
DK (2) DK3549599T5 (fr)
EA (1) EA036255B1 (fr)
ES (2) ES2965207T3 (fr)
FI (1) FI3549599T3 (fr)
GB (1) GB201315487D0 (fr)
HR (2) HRP20231264T1 (fr)
HU (2) HUE064437T2 (fr)
IL (1) IL244043B (fr)
LT (2) LT3038643T (fr)
MA (2) MA38930A1 (fr)
MX (1) MX372950B (fr)
MY (1) MY172484A (fr)
NZ (1) NZ717399A (fr)
PE (2) PE20201067A1 (fr)
PH (1) PH12016500275B1 (fr)
PL (2) PL3038643T3 (fr)
PT (2) PT3038643T (fr)
RS (2) RS59019B1 (fr)
SG (1) SG11201601151PA (fr)
SI (2) SI3038643T1 (fr)
SM (2) SMT201900471T1 (fr)
TN (1) TN2016000067A1 (fr)
TR (1) TR201909478T4 (fr)
TW (1) TWI531582B (fr)
UA (1) UA118354C2 (fr)
UY (1) UY35718A (fr)
WO (1) WO2015028455A1 (fr)
ZA (1) ZA201601437B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201315487D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
JP6851322B2 (ja) * 2015-05-27 2021-03-31 ユーシービー バイオファルマ エスアールエル 神経疾患を治療する方法
HK1249016A1 (zh) * 2015-06-02 2018-10-26 豪夫迈‧罗氏有限公司 使用抗il-34抗体治疗神经疾病的组合物和方法
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3824906A1 (fr) 2016-12-21 2021-05-26 Amgen Inc. Formulations d'anticorps anti-tnf alpha
WO2018183366A1 (fr) 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Polythérapies d'anticorps csf-1r ou csf-1 et thérapie reposant sur des lymphocytes t
US12168054B2 (en) 2017-05-19 2024-12-17 Syndax Pharmaceuticals, Inc. Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody
GB201803226D0 (en) 2018-02-28 2018-04-11 Ultrahuman Twelve Ltd CSF1R Binding agents
CN109096397B (zh) * 2018-07-18 2019-04-16 博奥信生物技术（南京）有限公司 一种抗人csf-1r单克隆抗体及应用
CN108948198B (zh) * 2018-07-18 2020-09-01 博奥信生物技术（南京）有限公司 抗人csf-1r单克隆抗体及其应用
EP3894014A4 (fr) * 2018-12-13 2022-04-20 Development Center for Biotechnology Anticorps anti-csf-1r humain et ses utilisations
CN113939539B (zh) * 2019-05-15 2024-06-04 博奥信生物技术（南京）有限公司 结合csf-1r的抗体及其用途
PH12022551401A1 (en) * 2019-12-09 2023-08-23 Syndax Pharmaceuticals Inc Antibodies for the treatment of chronic graft versus host disease
CN114835811B (zh) * 2019-12-24 2024-03-26 宝船生物医药科技(上海)有限公司 抗csf1r分子及其用途
CN121219009A (zh) 2023-05-17 2025-12-26 信达克思制药公司 使用抗集落刺激因子1受体抗体治疗慢性移植物抗宿主病相关的闭塞性细支气管炎综合征的方法
AU2024300057A1 (en) 2023-07-23 2026-01-08 Incyte Corporation Methods of treating chronic graft-versus-host disease using an anti-colony stimulating factor 1 receptor antibody
TW202544045A (zh) 2024-04-22 2025-11-16 美商英塞特公司 抗群落刺激因子１受體抗體與ｊａｋ抑制劑之組合療法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2090126C (fr) 1990-08-02 2002-10-22 John W. Schrader Methodes de production de proteines dotees d'une fonction desiree
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
WO2004051268A1 (fr) 2002-12-03 2004-06-17 Celltech R & D Limited Dosage biologique permettant d'identifier des cellules productrices d'anticorps
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
PT1644412E (pt) 2003-07-01 2015-12-23 Ucb Biopharma Sprl Fragmentos de anticorpos fab modificados
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2005014655A2 (fr) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugues d'amidon d'hydroxyalkyle et de proteine
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
JP5718640B2 (ja) * 2007-08-21 2015-05-13 アムジエン・インコーポレーテツド ヒトｃ−ｆｍｓ抗原結合性タンパク質
EP2535350B1 (fr) 2007-09-26 2018-01-24 UCB Biopharma SPRL Fusions d'anticorps à double spécificité
JO3240B1 (ar) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
RU2547586C2 (ru) 2008-03-14 2015-04-10 Трансжене С.А. Антитело против csf-1r
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
US10407513B2 (en) 2008-09-26 2019-09-10 Ucb Biopharma Sprl Biological products
WO2011030107A1 (fr) 2009-09-10 2011-03-17 Ucb Pharma S.A. Anticorps multivalents
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
DK2510010T3 (en) * 2009-12-10 2015-12-14 Hoffmann La Roche Antibodies that bind to human CSF1R extracellular domain 4 and their use
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
CN102918061B (zh) * 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
AR080698A1 (es) * 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
EP3943154A1 (fr) * 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Anticorps se liant au csf1r
MX356337B (es) * 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
GB201315486D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
GB201315487D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies

Also Published As

Publication number Publication date
JP2016529266A (ja) 2016-09-23
UA118354C2 (uk) 2019-01-10
TN2016000067A1 (en) 2017-07-05
EP3549599B1 (fr) 2023-09-06
RS64784B1 (sr) 2023-11-30
FI3549599T3 (fi) 2023-10-31
WO2015028455A1 (fr) 2015-03-05
SI3038643T1 (sl) 2019-08-30
AR097464A1 (es) 2016-03-16
CN105658236A (zh) 2016-06-08
TW201512221A (zh) 2015-04-01
EA201690503A1 (ru) 2016-06-30
EP4282881A2 (fr) 2023-11-29
BR112016004324A2 (pt) 2017-10-24
JP7195237B2 (ja) 2022-12-23
PH12016500275A1 (en) 2016-05-02
GB201315487D0 (en) 2013-10-16
CA2922240A1 (fr) 2015-03-05
JP2020005652A (ja) 2020-01-16
IL244043A0 (en) 2016-04-21
PH12016500275B1 (en) 2019-11-29
EP3038643B1 (fr) 2019-05-01
EP4282881A3 (fr) 2024-02-21
ES2965207T3 (es) 2024-04-11
CN112321711B (zh) 2024-11-08
CL2016000438A1 (es) 2016-11-11
CN112321711A (zh) 2021-02-05
HRP20231264T1 (hr) 2024-02-02
NZ717399A (en) 2021-12-24
RS59019B1 (sr) 2019-08-30
LT3038643T (lt) 2019-07-25
US10421814B2 (en) 2019-09-24
EP3549599A1 (fr) 2019-10-09
UY35718A (es) 2015-03-27
LT3549599T (lt) 2023-11-10
TWI531582B (zh) 2016-05-01
US20180162947A1 (en) 2018-06-14
JP2022002523A (ja) 2022-01-11
AU2014314304A1 (en) 2016-03-17
PE20201067A1 (es) 2020-10-19
AR134186A2 (es) 2025-12-10
KR102303130B1 (ko) 2021-09-16
HK1220142A1 (en) 2017-04-28
KR20160044018A (ko) 2016-04-22
DK3038643T3 (da) 2019-06-24
US9908939B2 (en) 2018-03-06
MY172484A (en) 2019-11-26
MA44922B1 (fr) 2020-06-30
ES2733735T3 (es) 2019-12-02
CY1121964T1 (el) 2020-10-14
MX372950B (es) 2020-04-03
HRP20191051T1 (hr) 2019-09-06
MA38930A1 (fr) 2017-12-29
TR201909478T4 (tr) 2019-07-22
US20160200821A1 (en) 2016-07-14
EA036255B1 (ru) 2020-10-20
JP6632075B2 (ja) 2020-01-15
PT3549599T (pt) 2023-11-21
HUE064437T2 (hu) 2024-03-28
MX2016002166A (es) 2016-06-23
PE20160528A1 (es) 2016-05-21
CA2922240C (fr) 2023-09-05
SMT202300409T1 (it) 2024-01-10
SI3549599T1 (sl) 2023-12-29
DK3549599T5 (da) 2024-09-02
IL244043B (en) 2021-01-31
EP3038643A1 (fr) 2016-07-06
BR112016004324B1 (pt) 2024-01-16
AU2014314304B2 (en) 2019-12-05
PT3038643T (pt) 2019-07-25
ZA201601437B (en) 2018-08-29
HUE045672T2 (hu) 2020-01-28
PL3038643T3 (pl) 2019-11-29
DK3549599T3 (en) 2023-10-30
PL3549599T3 (pl) 2024-03-04
SMT201900471T1 (it) 2019-09-09
CN105658236B (zh) 2021-03-19
SG11201601151PA (en) 2016-03-30

Similar Documents

Publication Publication Date Title
MA44922B1 (fr) Anticorps
MA39096B1 (fr) Anticorps spécifiques à fcrn
EA201892774A1 (ru) Антитела
ATE516814T1 (de) 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
SG10201907215QA (en) Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
UA108912C2 (uk) БІЛОК, ЯКИЙ ЗВ'ЯЗУЄ TNF-α
BR112020002012A8 (pt) Anticorpos anti-cd39, composições que compreendem anticorpos anti-cd39 e métodos de utilização de anticorpos anti-cd39
EA202092589A3 (ru) Cxcr2-связывающие полипептиды
MA38308A1 (fr) Molécules de liaison à l'antigène bispécifiques activant des lymphocytes t
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
EA201590910A1 (ru) Белки на основе структурного домена фибронектина, связывающие pcsk9
PH12019500571A1 (en) Anti-pd-1 antibodies
MA38400A1 (fr) Molécules fc bispécifiques
PH12014502274B1 (en) Anti-fcrn antibodies
MA37407B1 (fr) Anticorps dirigés contre les ligands des récepteurs b1 de la bradykinine
JO3623B1 (ar) البروتينات المرتبطة بمولد المستضاد st2
MA38828A1 (fr) Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations
MX2018000447A (es) Novedosas proteinas especificas para lag-3.
MX384222B (es) Matriz de cromatografia de afinidad.
EP4375297A3 (fr) Anticorps contre le facteur c2b du complément humain et procédés d'utilisation
MX381725B (es) Medicamento que comprende anticuerpo anti-fosfolipasa d4.
EA201591898A1 (ru) Антитела, направленные на m-csf
Wu et al. The Research on Labor force Transfer Policy to Promote Urbanization-Based on the Analysis of Survey Data in Guangdong Province
MA39188A1 (fr) Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci
BR112015023429A2 (pt) anticorpo isolado ou fragmento de ligação de antígeno do mesmo, polinucleotídeo isolado, vetor de expressão, linhagem de célula, composição farmacêutica e uso de um anticorpo ou fragmento de ligação de antígeno do mesmo